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Background
Atopic dermatitis (AD) is an inflammatory, chronically
relapsing, and highly pruritic skin disorder that
considerably effects patients’ life. As the aeroallergens are
relevant eliciting factors of not only respiratory allergy
but also AD, allergen-specific immunotherapy (ASIT)
seems to be a curative therapy option in treating AD.
The efficacy of ASIT in AD patients has been poorly
investigated but the result are promising. We present the
pioneer study on the long-term efficacy of ASIT in AD.
The actual ASIT evaluation was performed after the
observational period of 2-12 years after the termination
of the treatment with allergy vaccines.
Method
Fifteen patients suffering from AD, allergic to house dust
mites or grass pollen allergens, who were previously
treated with ASIT participated in the study. The analysis
was performed based on selected clinical and laboratory
parameters, quality of life and need for medication. The
actual results were compared to those before ASIT was
introduced as well as with those after its termination. To
evaluate the skin condition W-AZS index was used. We
investigated allergy parameters (total IgE and specific IgE)
and immunological parameters (IL-2R, IL-4, IL-5, IL-10,
INF- g and ECP) .The quality of life evaluation was based
on DLQI questionnaire. The need for antihistamine
drugs, topical glicocorticosteroids as well as emollients
was assessed.
Results
Correctly performed ASIT in AD patients lead to quality
of life improvement that persists even after 2-12 years
after the termination of treatment. The improved quality
of life involves everyday life comfort, social and profes-
sional life. ASIT improves skin condition, reduces pruri-
tus during the treatment and,what is important, it leads
to continuing long-term improvement after its termina-
tion. As a result the need for antihistamine drugs,topical
glicocorticosteroids as well as emollients reduces and it
persists at a constant level for years. ASIT does not
affect the total and specific IgE at any level of observa-
tion. In a long term evaluation ASIT supresses a Th2
respond (IL-4,Il-5,IL-10) as well as Th1 respond (IL-2R,
INF-g) although the statistical analysis does not always
reveal the significant difference. The ECP reduction con-
firms the anti-inflammatory effect of ASIT.
Conclusion
This study confirms the effectiveness of ASIT in AD
patients and it discloses the persistence of its results in
long-term aspect.
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